Rockland Immunochemicals Inc. announced the acquisition of the TrueBlot IP/Western blot product line from eBioscience, Inc., an Affymetrix company. Western blotting, a critical assay that is a widely accepted analytical technique in both scientific research and medical diagnosis, is used to determine expression and quantitate target proteins in biological samples.
Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drugmaker of marketing the anemia treatment Aranesp for unapproved uses. The Thousand Oaks, Calif., company pleaded guilty to illegally introducing a misbranded drug into interstate commerce.
MedImmune has signed an in-licensing agreement with Progenics Pharmaceuticals Inc. for Progenics’ Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune’s Infectious Diseases & Vaccines Innovative Medicines Unit.
Tokai Pharmaceuticals Inc. announced the treatment of the first patient in the ARMOR2 trial, a Phase 2 clinical study of its lead candidate galeterone in patients with castration-resistant prostate cancer. ARMOR2 is Tokai’s second study to evaluate galeterone.
PDC Biotech GmbH has successfully completed a Phase 1 clinical trial for its lead compound for the treatment of preterm labor. This study was designed to evaluate safety as well as provide proof-of-concept for the ability of the compound to inhibit excessive uterine contractility.
Biotron has completed the clinical stage of a Phase 1b/2a trial of its lead HIV drug candidate, BIT225. Patients enrolled in the trial were HIV-positive, with high levels of virus and good CD4 T cell counts, and had not previously received treatment with anti-retroviral drugs.
An approach to diabetes that combines insulin and an inhibitor of the epidermal growth factor betacellulin could limit the progression of diabetic macular edema. Thwarting "cross-talk" between insulin and betacellulin promotes the regeneration of pancreatic beta cells that stores and releases insulin.
Shire plc announces a positive outcome from the European Decentralised Procedure for Elvanse. Elvanse is indicated as part of a comprehensive treatment program for attention deficit/hyperactivity disorder when response to previous methylphenidate treatment is considered clinically inadequate.
Global research and development (R&D) spending is forecast to grow by 3.7%, or $53.7 billion in 2013 to $1.5 trillion, according to the closely watched forecast by Battelle and R&D Magazine. The full report can be found here.
Scientists have identified a set of proteins circulating in blood whose levels accurately flag the presence of lymphedema. Lymphedema is an often-painful inflammatory condition resulting from the blockage of lymphatic vessels that ordinarily drain fluid from the tissues throughout the body.
Eli Lilly said that its board authorized a $1.5 billion share repurchase program, which the company expects to complete next year. All purchases under the new buyback program will be made on the open market. The company recently completed a $3 billion share repurchase program.
Myriad Genetics announced that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia. Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.
Scientists have long sought to understand how a DNA repair protein known as RecA in bacterial cells, helps broken DNA bridge the gap. They knew that RecA guided a broken DNA strand to a matching sequence on an adjoining bit of double-stranded DNA, but they didn’t know how.
BlueScreen HC from Gentronix Ltd. uses genetically modified, human-derived cells to detect the genotoxic effects of compounds. The assay builds flexibility into the use of GADD45a assays for pharmaceutical, personal care, and consumer product testing.